Current Research Studies

Cancer – SC-4017: A Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Condition or Therapy:

cancer, medullary thyroid cancer, infantile myofibromatosis, infantile fibrosarcoma, papillary thyroid cancer, soft tissue sarcoma, LOXO-292 therapy


Cancer and Blood Disorders
Study Number: SC-4017


What is the goal of this study?

Researchers want to determine safety of LOXO-292 and overall response rate to LOXO-292

Who can join the study?

This study may be a good fit for children and young adults who:

  • Are between 6 months to 21 years old, and 
  • Have advanced or metastatic solid or primary CNS tumor which has failed standard of care therapies
  • Have evidence of an activating RET gene alteration in the tumor and/ or blood

What will happen if my child takes part in this study?

You can read more about this study on

Who can I contact for more information?

To learn more, call 206-987-2106 or email the study coordinator.

Study Location(s):

Seattle Children's Main Hospital Campus

Principal Investigator:

Dr. Katie Albert
Research Center: Center for Clinical and Translational Research